Exploring the potential benefits of multi-field IMPT for stage I NSCLC SBRT: An in silico dosimetric comparison to IMRT and CyberKnife

探索多野IMPT在I期非小细胞肺癌SBRT中的潜在优势:与IMRT和CyberKnife的计算机剂量学比较。

阅读:1

Abstract

PURPOSE: Multi-field intensity-modulated proton therapy (IMPT) is a novel treatment protocol design method proposed to reduce range uncertainty. This study aimed to investigate whether multi-field IMPT has a dose distribution advantage over photon intensity-modulated radiation therapy (IMRT) and CyberKnife in stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC). METHODS: Twenty-nine patients who underwent photon SBRT from February 2021 to September 2022 at Shandong Cancer Hospital were included. Their Computed Tomography (CT) images were used to design CyberKnife and multi-field IMPT plans. For the photon plan (IMRT and CyberKnife), the planning target volume (PTV), which was extended from the internal gross target volume (IGTV), was prescribed at 50 Gy. For the proton plans, the planning beam-specific target volume (PBSTV) based on the IGTV was created to meet the same area as the photon PTV. Multi-field IMPT was simulated by adding additional beam angles to conventional IMPT. Dose distribution assessment factors included D(mean) and dose gradient index (GI) for PTV/PBSTV, and D(mean) and the hottest 0.1 cm(3) dose (D(0.1cc)) for organs at risk (OARs). RESULTS: With each patient receiving 7-11 beams, multi-field IMPT had a better target GI than IMRT. For the lung, heart, spinal cord, chest wall, and ribs doses, the D(mean) of the multi-field IMPT was smaller than that of the other two plans for all metrics. CyberKnife was significantly less protective of the OARs than the other two planning modalities, owing to the presence of a high target center dose. CONCLUSION: Multi-field IMPT achieves favorable target coverage and OAR protection compared to IMRT and CyberKnife for SBRT of NSCLC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。